Clarivate Demonstrates Global Demand For AI-native Web Of Science Research Intelligence
Clarivate Demonstrates Global Demand For AI-native Web Of Science Research IntelligencePR NewswireLONDON, Oct. 22, 2026More than 100 institutions across 25 coun
CLVT - Clarivate Plc
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$2.00
DETAILS
HIGH:
$2.00
LOW:
$2.00
MEDIAN:
$2.00
CONSENSUS:
$2.00
UPSIDE:
6.95%
Stock News
Clarivate Demonstrates Global Demand For AI-native Web Of Science Research Intelligence
More than 100 institutions across 25 countries and regions are using the AI-native research intelligence platform. LONDON, Oct. 22, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced that more than 100 institutions across 25 countries and regions have adopted Web of Science Research Intelligence, highlighting growing global customer demand since the platform launched in May 2026.
Clarivate PLC (NYSE:CLVT) Stock Has Consensus Price Target of $3.02 According to Analysts
Shares of Clarivate PLC (NYSE: CLVT - Get Free Report) have been assigned a consensus rating of "Reduce" from the eight research firms that are currently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating
Sterne Kessler and Clarivate Announce Partnership to Develop AI-enhanced Patent Workflow Solutions
WASHINGTON--(BUSINESS WIRE)--Sterne, Kessler, Goldstein & Fox (Sterne Kessler), a market leading intellectual property (IP) law firm, today announced a co-development partnership with Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, to develop AI-enhanced patent workflow solutions. This partnership brings together Sterne Kessler's practitioner-built technology and deep patent practice expertise with Clarivate's leading IP data and software. Together, the.
Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation
Transaction sharpens strategic focus on leading Academia & Government and Intellectual Property segments Proceeds strengthen balance sheet and enhance financial flexibility LONDON, Oct. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate" or the "Company"), a leading global provider of transformative intelligence, today announced the successful completion of the sale of its Life Sciences & Healthcare segment to Altaris, LLC ("Altaris"), advancing Clarivate's transformation and simplifying its portfolio. The transaction for $600 million was previously announced on July 6, 2026.
Clarivate (NYSE:CLVT) Hits New 12-Month Low – What’s Next?
Clarivate PLC (NYSE: CLVT - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Monday. The stock traded as low as $1.47 and last traded at $1.4650, with a volume of 5159 shares traded. The stock had previously closed at $1.48. Wall Street Analyst Weigh In Several brokerages have weighed in
Clarivate Announces Final Results of Offer to Purchase for Cash Certain of its Outstanding Debt Securities
LONDON, Sept. 24, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced the expiration and final results of its previously announced cash tender offer (the "Offer") by its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), to purchase the outstanding 3.875% Senior Secured Notes due 2028 (the "Notes") for aggregate principal amount of up to $75,000,000 (the "Maximum Amount"), upon the terms and subject to the conditions set forth in the Offer to Purchase dated September 17, 2026 (the "Offer to Purchase") and any related documents (collectively with the Offer to Purchase, the "Tender Offer Documents").
Clarivate Announces Pricing Terms of Offer to Purchase for Cash Certain of its Outstanding Debt Securities
LONDON, Sept. 23, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced the Reference Yield and Total Consideration (as set forth in the table below) to be paid in connection with its previously announced cash tender offer (the "Offer") by its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), to purchase the outstanding notes described below, upon the terms and subject to the conditions set forth in the Offer to Purchase dated September 17, 2026 (the "Offer to Purchase").
Clarivate to Report Third Quarter 2026 Results on November 3, 2026
LONDON, Sept. 22, 2026 /PRNewswire/ -- (PR Newswire) - Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced it will report its financial results for the third quarter 2026 before the market opens on Tuesday, November 3, 2026.
Clarivate PLC (NYSE:CLVT) Receives $3.02 Consensus Price Target from Brokerages
Shares of Clarivate PLC (NYSE: CLVT - Get Free Report) have earned a consensus recommendation of "Reduce" from the seven brokerages that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation and one has issued a buy recommendation on the company.
Clarivate Commences Offer to Purchase for Cash Certain of its Outstanding Debt Securities
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), has commenced a cash tender offer (the "Offer") to purchase the outstanding notes described below, upon the terms and subject to the conditions set forth in the Offer to Purchase dated September 17, 2026 (the "Offer to Purchase").
Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs
Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific BreakthroughsPR NewswireLONDON, Sept. 17, 202622 researchers honored for Nobel-c
Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs
22 researchers honored for Nobel-class discoveries, including pioneers of GLP-1 medicines and other world-changing advances LONDON, Sept. 17, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the Citation Laureates 2026, a distinguished group of 22 researchers whose work is of Nobel class.
Accuserve Solutions Appoints Maroun S. Mourad as an Independent Board Member
Veteran Insurance Executive Brings Carrier Relationships and Data Analytics Expertise to Support Accuserve's Continued Growth and Its Mission to Simplify the Claims Experience DENVER, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Accuserve Solutions (“Accuserve” or the “Company”), an independent managed repair services platform connecting insurance carriers, homeowners, and contractors, today announced the appointment of Maroun S.
Clarivate Director Cornick Buys 900,000 Shares for $1.7 Million. What Does This Tell Investors About the Outlook for 2026?
Cornick's purchase increased his total holdings by 74% despite stock declining 52% over the past year, signaling conviction in the company's recovery prospects.
Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development
Expanded capabilities across Cortellis portfolio help life sciences organizations turn trusted intelligence into action and accelerate decision making across the research and development lifecycle LONDON, Aug. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the expansion of agentic AI capabilities across the Cortellis portfolio, helping life sciences R&D teams accelerate discovery, strengthen safety assessment and make faster, more informed portfolio decisions. By embedding AI directly within existing workflows, the new capabilities enable researchers to reduce manual effort, navigate complexity and focus on higher-value scientific and strategic decisions.
First Trust Advisors LP Has $13.97 Million Stock Holdings in Clarivate PLC $CLVT
First Trust Advisors LP lifted its stake in shares of Clarivate PLC (NYSE: CLVT) by 10.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,522,601 shares of the company's stock after acquiring an additional 516,418 shares during the quarter.
Clarivate Q2 Earnings Call Highlights
Clarivate NYSE: CLVT said during its earnings call that it expects organic recurring revenue and annualized contract value growth to improve in the second half of the year, citing renewal visibility, product momentum and a growing pipeline of AI-enabled offerings.
Clarivate Plc (CLVT) Q2 2026 Earnings Call Transcript
Clarivate Plc (CLVT) Q2 2026 Earnings Call Transcript
Clarivate (CLVT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Clarivate (CLVT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Price Targets
Clarivate price target lowered to $2 from $2.50 at Barclays
$2.00
(was $2.15)
Manav Patnaik
·
Barclays
Clarivate price target raised to $2.50 from $2.40 at Barclays
$2.50
(was $2.44)
Manav Patnaik
·
Barclays
Clarivate downgraded to Neutral from Buy at Goldman Sachs
$3.60
(was $3.36)
Goldman Sachs
Clarivate downgraded to Underweight from Equal Weight at Morgan Stanley
$3.00
(was $3.57)
Morgan Stanley
Clarivate price target lowered to $4.20 from $4.80 at Goldman Sachs
$4.20
(was $3.35)
Goldman Sachs
Clarivate Is Oversold Stock Brimming with Turnaround Potential, Analyst Predicts
$11.00
(was $8.98)
Owen Lau
·
Oppenheimer
Morgan Stanley Downgrades Clarivate to Equal-Weight, Raises Price Target to $12
$12.00
(was $11.19)
Morgan Stanley
Goldman Sachs Maintains Buy on Clarivate, Lowers Price Target to $20
$20.00
(was $17.07)
Goldman Sachs